Summary
RNA Chart
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago.
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?
Avidity Biosciences (RNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avidity Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 19 | $254 | $254 | - | - |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 21 | $280 | $280 | - | - |
 Kasey Fegan Corsicana & Co. | 9,820 | $125,205 | $111,457 | -$13,748 | -10.98% |
 Joseph Castro Nuveen LLC | 31,071 | $415,880.81 | $417,905 | $2,024.19 | 0.49% |
 Ana-Maria Ignat Covestor Ltd | 466 | $6 | $6 | - | - |
Avidity Biosciences Inc. (RNA) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Avidity Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kathleen Gallagher CEO | NASDAQ (NMS) Exchange | 04965N104 CUSIP |
| US Country | 511 Employees | - Last Dividend | - Last Split | 28 Jun 2013 IPO Date |
Overview
Avidity Biosciences, Inc. is a biopharmaceutical company founded in 2012 and based in San Diego, California. The company specializes in the development of RNA therapeutics, focusing on a novel approach using antibody oligonucleotide conjugates (AOC). These AOCs are designed to deliver RNA therapeutics directly to specific cells, targeting diseases that have been previously considered untreatable through RNA-based strategies. Avidity's leading efforts are directed towards addressing rare monogenic muscle diseases and cardiac diseases through their cutting-edge AOC technology.
Products and Services
Avidity Biosciences, Inc. is working on multiple promising product candidates in various stages of clinical development:
- AOC 1001 - This is the company's lead product candidate, currently in a phase 1/2 clinical trial. It is being developed for the treatment of myotonic dystrophy type 1, which is a rare monogenic muscle disease. AOC 1001 represents a pioneering approach in treating this condition by targeting the underlying genetic causes with RNA therapeutics.
- AOC 1044 - Aimed at treating Duchenne muscular dystrophy, AOC 1044 is under phase 1/2 clinical development. This product embodies Avidity's dedication to combating rare skeletal muscle diseases by leveraging their proprietary AOC technology to potentially offer a new form of therapy for patients suffering from this debilitating condition.
- AOC 1020 - This product is currently in a phase 1/2 clinical trial for the treatment of facioscapulohumeral muscular dystrophy, another rare muscle disease. AOC 1020 is part of Avidity's broader mission to develop therapies for rare skeletal muscle and cardiac diseases that have limited treatment options, showcasing the company’s commitment to addressing unmet medical needs through innovative RNA therapeutics.
